Literature DB >> 8820178

The role of estrogen in schizophrenia.

M V Seeman1.   

Abstract

This paper reviews 3 recent studies from different clinics correlating psychotic symptoms with phases of the menstrual cycle in women with schizophrenia. The aim of the paper is to focus on the estrogen protection hypothesis which would suggest that low estrogen phases correlate with more severe symptoms, and high estrogen phases correlate with less severe symptoms. Although the methodology of the 3 studies was different, the hypothesis was essentially upheld. High levels of estrogens protect against symptom exacerbations in women with schizophrenia. A corollary to this finding is that, for optimal efficacy and safety, neuroleptic doses could be reduced at certain times of the month and increased at others.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820178      PMCID: PMC1188751     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  51 in total

1.  Variation in symptom severity over the menstrual cycle of schizophrenics.

Authors:  J D Hallonquist; M V Seeman; M Lang; N A Rector
Journal:  Biol Psychiatry       Date:  1993-02-01       Impact factor: 13.382

2.  Oestrogens and extrapyramidal system.

Authors:  P Bedard; P Langelier; A Villeneuve
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

3.  Sex differences in the familial transmission of schizophrenia.

Authors:  J M Goldstein; S V Faraone; W J Chen; G S Tolomiczencko; M T Tsuang
Journal:  Br J Psychiatry       Date:  1990-06       Impact factor: 9.319

4.  Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.

Authors:  M H Chakos; D I Mayerhoff; A D Loebel; J M Alvir; J A Lieberman
Journal:  Psychopharmacol Bull       Date:  1992

Review 5.  Schizophrenia and oestrogens--is there an association?

Authors:  A Riecher-Rössler; H Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

6.  Evidence for a gender bias in epidemiological studies of schizophrenia.

Authors:  M Hambrecht; K Maurer; H Häfner
Journal:  Schizophr Res       Date:  1993-01       Impact factor: 4.939

7.  Acute psychiatric admission related to the menstrual cycle.

Authors:  R Luggin; L Bernsted; B Petersson; A T Jacobsen
Journal:  Acta Psychiatr Scand       Date:  1984-06       Impact factor: 6.392

8.  Gender differences in the clinical expression of schizophrenia.

Authors:  D L Shtasel; R E Gur; F Gallacher; C Heimberg; R C Gur
Journal:  Schizophr Res       Date:  1992-09       Impact factor: 4.939

9.  Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia.

Authors:  R Prudo; H M Blum
Journal:  Br J Psychiatry       Date:  1987-03       Impact factor: 9.319

10.  Patterns of sex differences in negative symptoms and social functioning consistent with separate dimensions of schizophrenic psychopathology.

Authors:  R H Dworkin
Journal:  Am J Psychiatry       Date:  1990-03       Impact factor: 18.112

View more
  17 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

2.  Diagnosing cycloid psychosis.

Authors:  L C Kopala
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

3.  Sex versus gender differences in schizophrenia: The case for normal personality differences.

Authors:  Richard Lewine; Morgan Martin; Mara Hart
Journal:  Schizophr Res       Date:  2017-02-16       Impact factor: 4.939

4.  Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle.

Authors:  Susan E Best; Philip M Sarrel; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; John P Seibyl; Robert B Innis; Christopher H van Dyck
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

5.  Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis.

Authors:  Katherine S F Damme; Ivanka Ristanovic; Teresa Vargas; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2020-04-30       Impact factor: 4.905

6.  Clinical features of schizophrenia in a woman with hyperandrogenism.

Authors:  L C Kopala; R Lewine; K P Good; M Fluker; J S Martzke; J S Lapointe; W G Honer
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

Review 7.  Estrogen action in mood and neurodegenerative disorders: estrogenic compounds with selective properties-the next generation of therapeutics.

Authors:  Marie K Osterlund; Michael-Robin Witt; Jan-Ake Gustafsson
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

Review 8.  The effects of early life stress on motivated behaviors: A role for gonadal hormones.

Authors:  Samantha R Eck; Debra A Bangasser
Journal:  Neurosci Biobehav Rev       Date:  2020-10-03       Impact factor: 8.989

Review 9.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.

Authors:  Michal Arad; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2009-01-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.